The removal of damaged material from within atherosclerotic plaques (“fatty streaks”) to restore cardiovascular health is a key component of SENS, now being developed for the clinic by SRF ally Underdog Pharmaceuticals. Exciting new preclinical results from another group using this strategy have recently been published in ACS Nano.
Defatting the Streaks
The removal of damaged material from within atherosclerotic plaques ("fatty streaks") to restore cardiovascular health is a key component of SENS, now being developed for the clinic by SRF ally Underdog Pharmaceuticals. Exciting new preclinical results from another group using this strategy have recently been published in ACS Nano.
Recent Posts:
More Studies on Metformin and Survival
Michael Rae
September 6, 2023
4:12 pm
Sponsor a Student
SRF
August 14, 2023
7:17 pm
Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials
Michael Rae
August 2, 2023
12:49 am
The Grand Opening of Our New Facilities
SRF
July 9, 2023
3:42 pm
From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done
Michael Rae
June 5, 2023
6:56 pm
Lights, Camera, Action on AI-Powered Drug Discovery
SRF
May 3, 2023
6:09 pm
Announcing the Biomarkers of Aging Consortium
SRF
March 10, 2023
12:56 pm
Action at the Governmental Level for Longevity
SRF
March 10, 2023
12:30 pm
Scenes from the Lab
SRF
March 8, 2023
5:16 pm
A Busy Spring in the Education Department
SRF
March 8, 2023
4:22 pm
New Peer-Reviewed Paper from SENS Research Foundation: Iron Homeostasis as a Senolytic Target
SRF
February 8, 2023
5:47 pm